Recent

% | $
Quotes you view appear here for quick access.

Sangamo Biosciences Inc. Message Board

rvga128 554 posts  |  Last Activity: 5 hours ago Member since: Dec 5, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Looks like the Motley Fool articale on ADXS

    by mastiffsforlife Aug 22, 2015 10:01 AM
    rvga128 rvga128 Aug 22, 2015 11:23 AM Flag

    Smasse response was great.

  • Reply to

    Financial Times:

    by rvga128 Aug 18, 2015 1:09 PM
    rvga128 rvga128 Aug 19, 2015 8:55 AM Flag

    Along with peers China Overseas Land and Investment and China Resources Land, Vanke trades on single-digit multiples of 2015 earnings, for growth in the low to mid teens. Cheap? That depends where we are in the cycle. Since April, property prices have merely stopped falling. If they resume their tumble, the low multiple will prove painfully deceptive.
    China’s economy looks shaky, with last week’s adjustment to the renminbi taken as a sign that it could be worse than feared. Still, macro data have been poor for some time — yet Vanke’s numbers were far from terrible. This year, supply has fallen much more sharply than demand. Figures from China’s National Bureau of Statistics show completed residential projects’ gross floor area (GFA) down 16 per cent year on year, even as the GFA of residential sales rose 7 per cent. The GFA for new projects commenced — which would become available in about a year — has fallen by nearly a fifth. Land purchases have collapsed by a third.
    Some of this is due to demand and supply mismatches: inventories in third tier cities remain high, curbing appetite for new projects. More vibrant top tier cities, such as Shenzhen which has led the turnround, look set to become supply constrained due to a scarce, and thus expensive, land bank.
    This lends itself to a bullish thesis for sector leaders. COLI, China Resources Land and Vanke have been disciplined with their balance sheets. Vanke’s net debt to equity is a mere 16 per cent. As the renminbi weakens, offshore debt may have lost its appeal but onshore demand is healthy, with about $14bn of renminbi debt raised so far this year.

  • China property: developing nicely
    Article on China housing

  • Reply to

    Maybe the bloodletting is over

    by yi71 Aug 17, 2015 3:28 PM
    rvga128 rvga128 Aug 17, 2015 6:51 PM Flag

    "Insecure dimwit" - you hit the nail on its head, unlike some longs on this board who are struggling with easy analysis.

  • yi71 • Apr 18, 2015 4:05 PM Flag
    0users liked this postsusers disliked this posts0Reply
    Thanks very much for taking the time to write such a detailed and informative reply. I'm impressed with how you discovered and took a chance with INO, buying at .5 for example. $5,000 racked up 10,000 shares. I have a few thousand shares of CYTR and also own some Ziop, ADXS, ARIA, CYTK and HTBX, all in the black. I got on the biotech bandwagon after a great experience with AVNR. AVNR already had an established FDA approved drug with high likelihood of getting approval for other indications and blockbuster sales. All these others are more speculative and risky. As you said, small market cap biotech companies offer the greatest gains but historically on a percentage basis few succeed in getting FDA approvals. Thanks again for your comprehensive comments about INO. The tip about following comments on Facebook is a good one. With the market poised to undergo a significant correction, these promising biotechs, even though highly speculative, might hold up, especially when driven by results of Phase II trials. Or they could crater if and when funds decide to take their profits and sell in droves, which creates new buying windows. In the meantime, aldoxorubicin trials have gone well and we can hope for great success with this stock. A lot of new money has poured in over the past week and the volume of trading brings a smile to our faces. The upgrade was a nice catalyst but CYTR was poised for big gains regardless. Good luck, and one more thanks for your INO analysis. Less
    Reply to Peeved by parisite76 •Apr 17, 2015

  • Reply to

    Maybe the bloodletting is over

    by yi71 Aug 17, 2015 3:28 PM
    rvga128 rvga128 Aug 17, 2015 6:39 PM Flag

    If he was any good he would not be touting CYTR and ADRO. The board has to recognize that he shut a normal slime.

  • rvga128 rvga128 Aug 16, 2015 5:39 PM Flag

    Just sharing about Eylea/REGN. You can draw your conclusions and I think you are capable of IT.
    ADXS is going to much greater then REGN.

  • rvga128 rvga128 Aug 16, 2015 5:37 PM Flag

    There are several anti-VEGF drugs available that are currently used to treat AMD, but three are most commonly used for the condition. Two of these, ranibizumab (brand name Lucentis®) and aflibercept (brand name Eylea®), were designed specifically for the treatment of AMD. A third drug, bevacizumab (brand name Avastin®), was originally developed to treat various types of cancer, but is commonly used "off-label" in patients with AMD.
    ------------------------------------------------------------------------------------------------------------------------------------
    FDA approval
    While Lucentis and Eylea have been FDA-approved for use in the eye, Genentech, the company that manufactures Avastin, as well as Lucentis, has not sought FDA approval for Avastin to be used as treatment of wet AMD.

    However, Avastin was FDA-approved as a treatment for colon cancer in February 2004, and since then has been used by ophthalmologists to treat wet AMD “off-label” with great results. In fact, half of ophthalmologists prescribe Avastin as a first-line treatment for wet AMD.
    --Cost
    Avastin, at approximately $50 per average treatment, is significantly less expensive for the patient than the alternatives (~$1,800 for Eylea and ~$2,000 for Lucentis).

    Eylea’s and Lucentis’ significantly higher price tags reflect the costly process of FDA approval for their intended use. Although Avastin carries a similarly high price tag when used for colon cancer, it is much less expensive as an eye treatment because only 1/40th of the drug is being used for each dose.

    Price is often a deciding factor for patients. The manufacturers of Lucentis and Eylea do offer some patient assistance programs to help subsidize costs. But for many individuals, the nearly $2,000 difference between these two drugs and Avastin can add up to thousands of dollars or more in out-of-pocket costs over the course of treatment. This cumulative price differential has been the main focus of media stories about the three drugs.

  • Reply to

    Dang..... Another three month low today.

    by purely_evil Jul 24, 2015 12:51 PM
    rvga128 rvga128 Aug 16, 2015 11:19 AM Flag

    Study found that 31 states have already made commitments that will significantly reduce their carbon outputs and 21 are on track to actually surpass the EPA’s first benchmarks for 2022.

    Moreover, 20 states are effectively more than halfway toward meeting their 2030 Clean Power Plan target, with 16 set to surpass those targets.What’s more, some of the states that are in the forefront of trying to block the new EPA rules – including Ohio, Michigan, Georgia, North Carolina and Alabama – are well along in meeting the new federal targets, according to the UCS analysis.

    In all, 15 states led by the attorney general of West Virginia asked a federal court on Thursday to temporarily block the new carbon emission goals while they mount a full legal challenge to the rule, according to the The Wall Street Journal.

    Many of those states are highly reliant on coal-generated power and emit high levels of carbon emissions that directly contribute to global warming. They face the toughest economic challenges in converting to alternative energy sources.

    Yet according to the new report, Ohio already is on track to meet 82 percent of the EPA goals by 2022 based on rate of emissions, Michigan is 63 percent of the way there, Arizona 84 percent and Georgia, North Carolina and South Carolina could end up achieving twice the federal target.
    -----------------------------------------------------------------------------------------------------------------
    So what that tell you, the whole of GOP, has been lying on issues which are good for America.
    Reinsurance companies have already started modelling for prices based on Global warming Predictions.

  • Reply to

    Busy Hiring more

    by observingthechaos Aug 14, 2015 8:08 PM
    rvga128 rvga128 Aug 15, 2015 6:58 PM Flag

    I get what you say. I am little slow in understanding things sometimes. But thanks for that info. I value your posts always.

  • Reply to

    Busy Hiring more

    by observingthechaos Aug 14, 2015 8:08 PM
    rvga128 rvga128 Aug 15, 2015 6:32 PM Flag

    No James, I think Advaxis and Biocon will co-produce the vaccine. Biocon is going to produce a lot of biosimilars to make it possible for biotech to reach masses even in western world.

  • Reply to

    Yi seek pro help

    by chinaman.nyc2003 Aug 15, 2015 5:58 PM
    rvga128 rvga128 Aug 15, 2015 6:29 PM Flag

    He is trying to make up for his losses in CYTR and ADRO, by being a short in ADXS.

  • Reply to

    Dang..... Another three month low today.

    by purely_evil Jul 24, 2015 12:51 PM
    rvga128 rvga128 Aug 15, 2015 4:24 PM Flag

    Give this info. toTRUMP and Walker will be forced to drop off the race, quickly.

  • Reply to

    Dang..... Another three month low today.

    by purely_evil Jul 24, 2015 12:51 PM
    rvga128 rvga128 Aug 15, 2015 4:23 PM Flag

    He is talking about talent- like Scott Walker, who has not completed his college.
    But then he is very smart in telling WI that he is conservative, yes socially. But fiscally he is a wheeler and dealer- who cut Univ. of WI budget by $250 Million, but gave $500 million help to Milwaukee Bucks new owners to build a new stadium, coming from the state and local govts. You see where his priorities are.

  • Reply to

    ADRO observation

    by justice_and_equality Aug 14, 2015 7:53 PM
    rvga128 rvga128 Aug 15, 2015 1:58 PM Flag

    I agree. China, sell and invest that money in like AVXL. Why do you want ADRO when you have superior ADXS.

  • rvga128 rvga128 Aug 15, 2015 10:31 AM Flag

    Can I put it another way. When the inferior science of ADRO is getting attention, the superior science company like ADXS is low risk and great price to own.

  • Reply to

    advice on IMUC

    by wasbill Aug 15, 2015 10:19 AM
    rvga128 rvga128 Aug 15, 2015 10:29 AM Flag

    ADXS is going to way ahead of IMUC or NWBO.

  • Reply to

    advice on IMUC

    by wasbill Aug 15, 2015 10:19 AM
    rvga128 rvga128 Aug 15, 2015 10:24 AM Flag

    Unlike in immune deviated diseases like in autoimmune and Allergy, cancer is a very different ANIMAL. Combination therapies are going to the way of therapy.

  • Reply to

    advice on IMUC

    by wasbill Aug 15, 2015 10:19 AM
    rvga128 rvga128 Aug 15, 2015 10:22 AM Flag

    I am invested in IMUC. So far NWBO had been better.

SGMO
7.85+0.10(+1.29%)Aug 28 3:59 PMEDT